At the end of 2023, Naogen Pharma SAS, a Young Innovative Company (JEI) based in Nantes, obtained Marketing Authorization (MA) from the French National Agency for the Safety of Medicines and Health Products (ANSM) for the drug it has developed.
Founded in 2016 by Jean-François Chatal, a pioneer in nuclear medicine, buds of the research and development work of GIP Arronax (radioisotope) and Lemer Pax (automatic injector), Naogen Pharma has been led by Sylvain Fanier since 2020. The company manufactures and is preparing to market its radiopharmaceutical drug for non-invasive functional imaging.
Backed by family offices (Sigma, Jamo, Auxitex, CMNP, Med-Innov, Altur, Le Doussal, Lafitte, Jacques), ICO Innov, a consortium of Grand Ouest banks (BPI, BPGO and CIC), the Pays de la Loire Region and the French State via a government grant, Naogen Pharma has benefited from over €10 million in financing, including €6.6 million in fundraising (equity) and €3.3 million in bank loans.
In 2023, Naogen Pharma had 15 employees under direct contracts, rising to 24 in 2024, to ensure GMP (Good Manufacturing Practice) production and commercial launch, thus demonstrating the
company’s determination to establish a long-term presence and contribute to the development of the industrial fabric, economic dynamism, strengthening of the healthcare ecosystem, European
leadership and international influence of the Pays de la Loire region in the radiopharmaceutical field.
This success of the radiopharmaceutical industry in the Pays de la Loire region is the fruit of many years of intense R&D efforts and investment in industrial production facilities, strongly supported by the French government and local authorities, notably through the funding of the “Quanticardi” (FUI) and “Go Radiopharma” (Plan de Relance) projects, and the “BioOuest Laennec” business incubator provided by Nantes University Hospital, through Nantes Métropole and Loire Océan Développement. In addition, it confirms the vocation of the Grand-Ouest Atlanpole Biotherapies healthcare cluster as a “project factory” to “product factory”, and the key role of the Atlanpole territorial HUB in supporting the growth of companies.
Contact
Sylvain Fanier
Président
s.fanier@naogen-pharma.com
Tel +336 07 59 01 67
Naogen Pharma SAS
Centre BioOuest Laennec
Rue du Moulin de la Rousselière
44800 Saint Herblain
www.naogen-pharma.com